Profile data is unavailable for this security.
About the company
Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
- Revenue in USD (TTM)0.00
- Net income in USD-89.98m
- Incorporated2017
- Employees136.00
- LocationCabaletta Bio Inc2929 Arch Street, Suite 600PHILADELPHIA 19104United StatesUSA
- Phone+1 (267) 759-3100
- Fax+1 (302) 655-5049
- Websitehttps://www.cabalettabio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CAMP4 Therapeutics Corp | 350.00k | -49.71m | 206.56m | 58.00 | -- | -- | -- | 590.17 | -2.55 | -2.55 | 0.0179 | 0.7707 | -- | -- | -- | 5,468.75 | -- | -- | -- | -- | -- | -- | -14,203.71 | -- | -- | -- | 0.0221 | -- | -- | -- | -11.54 | -- | -- | -- |
| TuHURA Biosciences Inc | 0.00 | -8.50m | 206.79m | 1.00 | -- | -- | -- | -- | -75.24 | -75.24 | 0.00 | 2.38 | 0.00 | -- | -- | 0.00 | -163.44 | -224.08 | -343.80 | -346.74 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 43.40 | -- | -- | -- |
| Tevogen Bio Holdings Inc | 0.00 | 57.92m | 208.19m | 17.00 | 3.25 | -- | -- | -- | 0.3758 | 0.3758 | 0.00 | -0.0452 | 0.00 | -- | -- | 0.00 | 1,217.57 | -- | -- | -- | -- | -- | -- | -- | -- | -702.58 | -- | -- | -- | -- | 99.69 | -- | -- | -- |
| Nuvectis Pharma Inc | 0.00 | -19.37m | 208.86m | 13.00 | -- | 18.67 | -- | -- | -1.16 | -1.16 | 0.00 | 0.5789 | 0.00 | -- | -- | 0.00 | -97.93 | -- | -140.00 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -16.64 | -- | -- | -- |
| Benitec Biopharma Inc | 0.00 | -22.37m | 209.64m | 16.00 | -- | 2.26 | -- | -- | -7.63 | -7.63 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -76.76 | -103.21 | -91.06 | -123.13 | -- | 152.10 | -- | -26,432.69 | -- | -- | 0.00 | -- | -100.00 | -- | -14.35 | -- | -15.35 | -- |
| Fulcrum Therapeutics Inc | 81.63m | -20.23m | 217.78m | 76.00 | -- | 0.7935 | -- | 2.67 | -0.3507 | -0.3507 | 1.31 | 4.40 | 0.2746 | -- | 29.13 | 1,074,079.00 | -6.81 | -50.55 | -7.14 | -55.91 | -- | -- | -24.79 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
| Tenaya Therapeutics Inc | 0.00 | -117.23m | 218.65m | 140.00 | -- | 1.94 | -- | -- | -1.44 | -1.44 | 0.00 | 1.42 | 0.00 | -- | -- | 0.00 | -70.20 | -- | -78.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.3388 | -- | -- | -- |
| Cabaletta Bio Inc | 0.00 | -89.98m | 219.33m | 136.00 | -- | 1.09 | -- | -- | -1.92 | -1.92 | 0.00 | 4.13 | 0.00 | -- | -- | 0.00 | -44.76 | -33.76 | -47.90 | -35.68 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.75 | -- | -- | -- |
| Trevi Therapeutics Inc | 0.00 | -44.32m | 223.68m | 25.00 | -- | 3.72 | -- | -- | -0.4412 | -0.4412 | 0.00 | 0.7815 | 0.00 | -- | -- | 0.00 | -53.78 | -47.39 | -58.89 | -54.41 | -- | -- | -- | -- | -- | -- | 0.001 | -- | -- | -- | 0.2984 | -- | -2.81 | -- |
| Nkarta Inc | 0.00 | -107.91m | 225.08m | 150.00 | -- | 0.4967 | -- | -- | -2.01 | -2.01 | 0.00 | 6.42 | 0.00 | -- | -- | 0.00 | -21.95 | -32.39 | -23.07 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Kyverna Therapeutics Inc | -100.00bn | -100.00bn | 228.25m | 112.00 | -- | 0.6844 | -- | -- | -- | -- | -- | 7.73 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.0042 | -- | -100.00 | -- | -108.93 | -- | -- | -- |
| Corbus Pharmaceuticals Holdings Inc | 0.00 | -34.97m | 228.73m | 19.00 | -- | 1.72 | -- | -- | -5.82 | -5.82 | 0.00 | 10.92 | 0.00 | -- | -- | 0.00 | -35.74 | -86.84 | -45.03 | -130.46 | -- | -- | -- | -769.76 | -- | -29.78 | 0.0794 | -- | -- | -- | -5.33 | -- | -- | -- |
| XBiotech Inc | 0.00 | -35.01m | 230.00m | 94.00 | -- | 1.17 | -- | -- | -1.15 | -1.15 | 0.00 | 6.46 | 0.00 | -- | -- | 0.00 | -15.53 | 31.88 | -16.32 | 33.27 | -- | -- | -- | 877.30 | -- | -- | 0.0484 | 0.00 | -100.00 | -- | 25.36 | -- | 24.30 | -- |
| Onkure Therapeutics Inc | 0.00 | -56.54m | 234.51m | 8.00 | -- | 0.7643 | -- | -- | -16.82 | -16.82 | 0.00 | 23.00 | 0.00 | -- | -- | 0.00 | -49.87 | -- | -53.42 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -48.95 | -- | -- | -- |
| Solid Biosciences Inc | 0.00 | -102.44m | 234.53m | 88.00 | -- | 1.37 | -- | -- | -3.04 | -3.04 | 0.00 | 4.29 | 0.00 | -- | -- | 0.00 | -51.66 | -49.99 | -57.25 | -56.25 | -- | -- | -- | -2,117.05 | -- | -- | 0.0081 | -- | -100.00 | -- | -11.67 | -- | -27.90 | -- |
| Enanta Pharmaceuticals Inc | 71.96m | -115.33m | 234.56m | 145.00 | -- | 1.57 | -- | 3.26 | -5.46 | -5.46 | 3.41 | 7.03 | 0.161 | -- | 5.32 | 496,275.90 | -25.80 | -14.56 | -30.05 | -15.62 | -- | -- | -160.27 | -54.96 | -- | -- | 0.0095 | -- | -8.07 | -17.45 | -9.91 | -- | 24.89 | -- |
Data as of Nov 08 2024. Currency figures normalised to Cabaletta Bio Inc's reporting currency: US Dollar USD
55.50%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Jennison Associates LLCas of 30 Sep 2024 | 5.63m | 11.53% |
| T. Rowe Price Investment Management, Inc.as of 30 Jun 2024 | 3.88m | 7.94% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 3.31m | 6.78% |
| Adage Capital Management LPas of 30 Jun 2024 | 3.04m | 6.22% |
| Alkeon Capital Management LLCas of 30 Jun 2024 | 2.62m | 5.36% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 2.55m | 5.23% |
| Fred Alger Management LLCas of 30 Jun 2024 | 2.52m | 5.17% |
| Polar Capital LLPas of 30 Jun 2024 | 1.25m | 2.57% |
| StemPoint Capital LPas of 30 Jun 2024 | 1.18m | 2.41% |
| Silverbay Capital Management LLCas of 30 Jun 2024 | 1.13m | 2.31% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
